Article Text

Download PDFPDF
Artificial intelligence and inflammatory bowel disease: practicalities and future prospects
  1. Johanne Brooks-Warburton1,2,
  2. James Ashton3,
  3. Anjan Dhar4,
  4. Tony Tham5,
  5. Patrick B Allen5,
  6. Sami Hoque6,
  7. Laurence B Lovat7,
  8. Shaji Sebastian8,9
  1. 1 Department of Clinical Pharmacology and Biological Sciences, University of Hertfordshire, Hatfield, UK
  2. 2 Gastroenterology Department, Lister Hospital, Stevenage, UK
  3. 3 Paediatric Gastroenterology, Southampton University Hospitals NHS Trust, Southampton, UK
  4. 4 Gastroenterology, County Durham & Darlington NHS Foundation Trust, Bishop Auckland, UK
  5. 5 Department of Gastroenterology, Ulster Hospital, Dundonald, UK
  6. 6 Department of Gastroenterology, Barts Health NHS Trust, London, UK
  7. 7 Division of Surgery & Interventional Science, University College London, London, UK
  8. 8 Department of Gastroenterology, Hull University Teaching Hospitals NHS Trust, Hull, UK
  9. 9 Hull York Medical School, Hull, UK
  1. Correspondence to Dr Johanne Brooks-Warburton, Department of Clinical Pharmacology and Biological Sciences, University of Hertfordshire, Hatfield, UK; johanne.brooks{at}


Artificial intelligence (AI) is an emerging technology predicted to have significant applications in healthcare. This review highlights AI applications that impact the patient journey in inflammatory bowel disease (IBD), from genomics to endoscopic applications in disease classification, stratification and self-monitoring to risk stratification for personalised management. We discuss the practical AI applications currently in use while giving a balanced view of concerns and pitfalls and look to the future with the potential of where AI can provide significant value to the care of the patient with IBD.

  • endoscopy
  • IBD clinical
  • computerised image analysis
  • genetics

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • JB-W and JA are joint first authors.

  • Twitter @johanne_brooks, @James_Ashton, @anjan_dhar6, @samiHoque2, @barrettsonline

  • Contributors JB-W organised the authors, did the literature review wrote and edited the manuscript. JA did the literature review, wrote the manuscript and designed all the figures. AD wrote the manuscript and edited the manuscript. TT did the literature review and reviewed the manuscript for content and edited. PBA reviewed the manuscript for content and edited. SH reviewed the manuscript for content and edited. LBL wrote the manuscript and provided significant editing input. SS wrote the manuscript and provided significant editing input.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests COIs: JB-W holds research grants from AbbVie, and has received speaker fees from Dr Falk Pharma. JA no COI to declareAD Advisory and consultancy for Pfizer UK, Tillotts Pharma UK, Dr Falk Pharma, Pharmacosmos, Takeda UK, Honoraria and Speaker Fees from Dr Falk Pharma, Pfizer, Janssen, Tillotts Pharma, Pharmacosmos, Takeda UKPBA received research grants from Pfizer and speaker fees from Takaeda, AbbVie, GSK, Janssen, MSD and Tillotts. TT no COI to declare. SH no COI to declare. LBL is a minor shareholder in Odin Vision since 2018SS holds research grants from Biogen, Takeda, AbbVie, Tillotts Pharma, Ferring and Biohit; served on the advisory boards of Takeda, AbbVie, Merck, Ferring, Pharmacocosmos, Warner Chilcott, Janssen, Falk Pharma, Biohit, TriGenix, Celgene and Tillotts Pharma; and has received speaker fees from AbbVie, Biogen, AbbVie, Janssen, Merck, Warner Chilcott and Falk Pharma.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles

  • UpFront
    R Mark Beattie